Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:39:48 17/02/2026 GMT			After hours 20:43:47
49.32 ^EUR	+7.35%		49.12	-0.39%

07:10pm	Bayer proposes $7.25 billion plan to settle Roundup cancer cases	RE
06:08pm	BAYER AG : Jefferies remains Neutral	ZD

JPMorgan Maintains 'Overweight' Rating on Bayer with €50 Target

Published on 01/19/2026 at 06:02 am GMT - Modified on 01/19/2026 at 06:36 am GMT

dpa-AFX - Translated by Marketscreener - See original

BAYER AG

+7.35%

NEW YORK (dpa-AFX) - US bank JPMorgan has maintained its "Overweight" rating on Bayer, with a price target of €50. Analyst Richard Vosser wrote on Sunday evening that the US Supreme Court's decision to accept the "Durnell" glyphosate case for review marks another significant step towards resolving the legal disputes surrounding the weedkiller. Bayer shares could rise by around 5 percent due to expectations of reduced provisions. Vosser sees the next catalyst on February 5, when Phase III study data for the anticoagulant Asundexian will be presented at the International Stroke Conference (ISC). He anticipates positive results, which is why he continues to label the shares with a "Positive Catalyst Watch"./rob/ag/gl

Original study publication: 18.01.2026 / 20:46 / GMT Initial distribution of the original study: 19.01.2026 / 00:15 / GMT

-----------------------

dpa-AFX Broker - the trader news from dpa-AFX

-----------------------

Latest news about Bayer AG

07:10pm	Bayer proposes $7.25 billion plan to settle Roundup cancer cases	RE
06:08pm	BAYER AG : Jefferies remains Neutral	ZD
06:08pm	Jefferies Maintains 'Hold' Rating on Bayer, Target Price at 25 Euros	DP
05:53pm	Bayer Shares Surge on Mass Settlement in US Cancer Lawsuits	DP
05:50pm	Bayer progresses in settling US Roundup litigation
05:40pm	Bayer Ups Provision for Roundup Settlement Proposal, Flags Negative Free Cash Flow in FY26	MT
05:18pm	Bayer Proposes $7.25 Billion Payments for US Class Settlement of Roundup Claims	MT
05:09pm	Bayer Expects Provisions to Increase to Nearly $14 Billion as It Aims to Settle All Roundup Cases	DJ
05:09pm	Bayer CEO says Roundup settlement is important addition to Supreme Court case	RE
04:50pm	Frankfurt Stocks Close: DAX Rises Late as Wall Street Rebounds	DP
04:43pm	Bayer Proposes $7.25 Billion Payments for US Class Settlement of Roundup Claims	MT
04:36pm	Bayer says Monsanto announces Roundup class settlement agreement	RE
04:29pm	Bayer Aims to Settle Weedkiller Suits With $10.5 Billion Payout, Bloomberg Says, Citing Sources	DJ
03:50pm	Bayer Shares Surge Following Reports of Settlement Offer	DP
03:48pm	Bayer to make $10.5 billion push to settle roundup cases, Bloomberg reports	RE

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release

More about the company